{"transactions":[{"id":782490,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-12T20:09:09.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":7763,"price":25.63,"value":198965.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":84161,"source":{"system":"sec-edgar","filing":"0001653881-26-000005","document":"wk-form4_1778616546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388126000005/wk-form4_1778616546.xml","form_type":"4"}},{"id":931194,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-27T01:21:28.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company."}],"balance_after":96000,"derivative":{"exercise_price":22.13,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001653881-26-000002","document":"wk-form4_1769476886.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388126000002/wk-form4_1769476886.xml","form_type":"4"}},{"id":931193,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-27T01:21:28.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the unvested portion of the Reporting Person's RSU grants."}],"balance_after":91924,"source":{"system":"sec-edgar","filing":"0001653881-26-000002","document":"wk-form4_1769476886.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388126000002/wk-form4_1769476886.xml","form_type":"4"}},{"id":955228,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:19:02.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":6552,"price":23.38,"value":153185.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":67924,"source":{"system":"sec-edgar","filing":"0001610717-26-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000161071726000002/form4.xml","form_type":"4"}},{"id":963188,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T22:35:22.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":5960,"price":22.1595,"value":132070.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the\ndate of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting\nperson."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":74476,"source":{"system":"sec-edgar","filing":"0001653881-25-000011","document":"wk-form4_1766097319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388125000011/wk-form4_1766097319.xml","form_type":"4"}},{"id":963187,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T22:35:22.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":6702,"price":21.8843,"value":146668.5786,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the\ndate of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting\nperson."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the unvested portion of the reporting person's RSU grants."}],"balance_after":80436,"source":{"system":"sec-edgar","filing":"0001653881-25-000011","document":"wk-form4_1766097319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388125000011/wk-form4_1766097319.xml","form_type":"4"}},{"id":987029,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-26T21:07:42.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":25,"value":125000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":87138,"source":{"system":"sec-edgar","filing":"0001653881-25-000007","document":"wk-form4_1764191259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388125000007/wk-form4_1764191259.xml","form_type":"4"}},{"id":1012068,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-29T12:54:18.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023."}],"balance_after":92138,"source":{"system":"sec-edgar","filing":"0001653881-25-000005","document":"wk-form4_1761742455.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000165388125000005/wk-form4_1761742455.xml","form_type":"4"}},{"id":1294498,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:30:21.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":150000,"derivative":{"exercise_price":13.33,"expiration_date":"2025-01-22","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001724521-25-000017","document":"wk-form4_1738013415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000017/wk-form4_1738013415.xml","form_type":"4"}},{"id":1294497,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:30:21.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":97138,"source":{"system":"sec-edgar","filing":"0001724521-25-000017","document":"wk-form4_1738013415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000017/wk-form4_1738013415.xml","form_type":"4"}},{"id":1314908,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:08:03.000Z","date":"2024-12-31","kind":"sale","planned":true,"acquired":false,"shares":3594,"price":15,"value":53910.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023."}],"balance_after":60138,"source":{"system":"sec-edgar","filing":"0001724521-25-000002","document":"wk-form4_1735938476.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000002/wk-form4_1735938476.xml","form_type":"4"}},{"id":1328851,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-18T01:36:19.000Z","date":"2024-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":10099,"price":16.08,"value":162391.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":63732,"source":{"system":"sec-edgar","filing":"0001724521-24-000180","document":"wk-form4_1734485773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000180/wk-form4_1734485773.xml","form_type":"4"}},{"id":1622652,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-23T22:49:44.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":73831,"source":{"system":"sec-edgar","filing":"0001724521-24-000057","document":"wk-form4a_1708728574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000057/wk-form4a_1708728574.xml","form_type":"4/A","original_submission_date":"2024-01-25"}},{"id":1670970,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T00:40:14.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":86600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":86600,"derivative":{"exercise_price":15.44,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":86600},"source":{"system":"sec-edgar","filing":"0001724521-24-000030","document":"wk-form4_1706229604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000030/wk-form4_1706229604.xml","form_type":"4"}},{"id":1670969,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-26T00:40:14.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":21300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":73131,"source":{"system":"sec-edgar","filing":"0001724521-24-000030","document":"wk-form4_1706229604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000030/wk-form4_1706229604.xml","form_type":"4"}},{"id":1687914,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-04T22:23:19.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":2004,"price":20,"value":40080.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023."}],"balance_after":51831,"source":{"system":"sec-edgar","filing":"0001724521-24-000009","document":"wk-form4_1704406978.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000009/wk-form4_1704406978.xml","form_type":"4"}},{"id":1703389,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:10:08.000Z","date":"2023-12-19","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":2808,"price":18.09,"value":50796.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":53835,"source":{"system":"sec-edgar","filing":"0001724521-23-000067","document":"wk-form4_1703106591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000067/wk-form4_1703106591.xml","form_type":"4"}},{"id":1703388,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:10:08.000Z","date":"2023-12-18","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":2749,"price":17.74,"value":48767.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":56643,"source":{"system":"sec-edgar","filing":"0001724521-23-000067","document":"wk-form4_1703106591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452123000067/wk-form4_1703106591.xml","form_type":"4"}},{"id":1860611,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-09T20:05:39.000Z","date":"2023-06-07","kind":"sale","planned":true,"acquired":false,"shares":4049,"price":20.04,"value":81141.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":59392,"source":{"system":"sec-edgar","filing":"0001209191-23-035740","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123035740/doc4.xml","form_type":"4"}},{"id":2046433,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-25T22:53:58.000Z","date":"2023-01-23","kind":"grant","acquired":true,"shares":138200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company."}],"balance_after":138200,"derivative":{"exercise_price":22.02,"expiration_date":"2033-01-22","underlying":"Common Stock","underlying_shares":138200},"source":{"system":"sec-edgar","filing":"0001209191-23-004875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123004875/doc4.xml","form_type":"4"}},{"id":2046432,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:53:58.000Z","date":"2023-01-23","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company."}],"balance_after":63441,"source":{"system":"sec-edgar","filing":"0001209191-23-004875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123004875/doc4.xml","form_type":"4"}},{"id":2083770,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:26.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":387,"price":31.23,"value":12086.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":11566,"source":{"system":"sec-edgar","filing":"0001209191-22-061762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122061762/doc4.xml","form_type":"4"}},{"id":2083769,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:26.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":2066,"price":30.66,"value":63343.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":11953,"source":{"system":"sec-edgar","filing":"0001209191-22-061762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122061762/doc4.xml","form_type":"4"}},{"id":2339914,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-10T22:08:17.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company."}],"balance_after":62500,"derivative":{"exercise_price":33.03,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001209191-22-017984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122017984/doc4.xml","form_type":"4"}},{"id":2339913,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-10T22:08:17.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company."}],"balance_after":22519,"source":{"system":"sec-edgar","filing":"0001209191-22-017984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122017984/doc4.xml","form_type":"4"}},{"id":2463981,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":224,"price":41.4238,"value":9278.9312,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7019,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2463980,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":171,"price":40.5732,"value":6938.0172,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7243,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2463979,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":88,"price":39.6719,"value":3491.1272,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7414,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2463978,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":138,"price":38.7877,"value":5352.7026,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7502,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2463977,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":131,"price":40.4565,"value":5299.8015,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7640,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2463976,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:22:49.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":354,"price":39.5916,"value":14015.4264,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7771,"source":{"system":"sec-edgar","filing":"0001209191-21-070565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121070565/doc4.xml","form_type":"4"}},{"id":2902495,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-20T21:10:42.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":75000,"derivative":{"exercise_price":36.73,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-21-004260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121004260/doc4.xml","form_type":"4"}},{"id":2902494,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-20T21:10:42.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-21-004260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121004260/doc4.xml","form_type":"4"}},{"id":3035588,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-09T20:53:46.000Z","date":"2020-09-09","kind":"purchase","acquired":true,"shares":5000,"price":21.5697,"value":107848.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.10 to $22.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-049846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120049846/doc4.xml","form_type":"4"}},{"id":3069788,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-04T22:53:37.000Z","date":"2020-08-03","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable in 48 equal monthly installments after August 1, 2020, subject to the Reporting Person's continued service to the Company."}],"balance_after":250000,"derivative":{"exercise_price":21.06,"expiration_date":"2030-07-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-20-044848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120044848/doc4.xml","form_type":"4"}},{"id":3100809,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-24T17:03:14.000Z","date":"2020-06-22","kind":"tax_withholding","acquired":false,"shares":2483,"price":9.67,"value":24010.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."}],"balance_after":161027,"source":{"system":"sec-edgar","filing":"0000899243-20-017558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320017558/doc4.xml","form_type":"4"}},{"id":3189102,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-01T17:16:19.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":118188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the \"Vesting Commencement Date\"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":118188,"derivative":{"exercise_price":5.95,"expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":118188},"source":{"system":"sec-edgar","filing":"0000899243-20-009854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320009854/doc4.xml","form_type":"4"}},{"id":3189101,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-04-01T17:16:19.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":29106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") which vest in equal annual installments over a three year period measured from March 30, 2020.   Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs which vest over time measured from the grant date."}],"balance_after":163510,"source":{"system":"sec-edgar","filing":"0000899243-20-009854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320009854/doc4.xml","form_type":"4"}},{"id":3246245,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option\n(Right to Buy)","published_at":"2020-02-26T17:48:43.000Z","date":"2020-02-24","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares vest pursuant to the following schedule:  Twenty Five  Percent (25%) of the shares subject to the option vested on September 5, 2018 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":110620,"derivative":{"exercise_price":3.43,"expiration_date":"2027-09-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-005933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320005933/doc4.xml","form_type":"4"}},{"id":3246244,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-02-26T17:48:43.000Z","date":"2020-02-24","kind":"exercise","acquired":true,"shares":10000,"price":3.43,"value":34300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 relates to the exercise of an in-the-money stock option with cash by Reporting Person."}],"balance_after":134404,"source":{"system":"sec-edgar","filing":"0000899243-20-005933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320005933/doc4.xml","form_type":"4"}},{"id":3407818,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-23T20:01:52.000Z","date":"2019-09-19","kind":"grant","acquired":true,"shares":28814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On September 26, 2017, Reporting Person was granted an option exercisable for 115,254  shares.  Twenty-five percent (25%) of the shares was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease.   On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved."}],"balance_after":28814,"derivative":{"exercise_price":3.43,"exercise_date":"2019-09-19","expiration_date":"2027-09-25","underlying":"Common Stock","underlying_shares":28814},"source":{"system":"sec-edgar","filing":"0000899243-19-024074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924319024074/doc4.xml","form_type":"4"}},{"id":3480050,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T16:17:11.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":116850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments measured from June 20, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":116850,"derivative":{"exercise_price":9,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":116850},"source":{"system":"sec-edgar","filing":"0001567619-19-013880","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000156761919013880/doc1.xml","form_type":"4"}},{"id":3480049,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-24T16:17:11.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":21075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"RSUs which vest 1/3 annually over 3 years measured from June 20, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,981 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2019."}],"balance_after":124404,"source":{"system":"sec-edgar","filing":"0001567619-19-013880","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000156761919013880/doc1.xml","form_type":"4"}},{"id":3791937,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-12T17:36:09.000Z","date":"2018-10-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares vest pursuant to the following schedule:  Twenty Five  Percent (25%) of the shares subject to the option vested on September 5, 2018 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":120620,"derivative":{"exercise_price":3.43,"expiration_date":"2027-09-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-18-026655","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924318026655/doc4.xml","form_type":"4"}},{"id":3791936,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2018-10-12T17:36:09.000Z","date":"2018-10-10","kind":"exercise","acquired":true,"shares":5000,"price":3.43,"value":17150.0,"ownership":{"direct":true},"balance_after":101348,"source":{"system":"sec-edgar","filing":"0000899243-18-026655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924318026655/doc4.xml","form_type":"4"}},{"id":3944262,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-05-07T18:24:48.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":1630,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1630},"source":{"system":"sec-edgar","filing":"0001140361-18-022049","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000114036118022049/doc1.xml","form_type":"4"}},{"id":3944261,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-07T18:24:48.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":1630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."}],"balance_after":96348,"source":{"system":"sec-edgar","filing":"0001140361-18-022049","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000114036118022049/doc1.xml","form_type":"4"}},{"id":3945569,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-04T18:26:13.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":30508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as to 25% of the shares on the one-year anniversary of May 2, 2018, and 1/48th of the shares shall vest on each monthly anniversary thereafter, subject to the optionee remainining a service provider to the Issuer on each such vesting date."}],"balance_after":30508,"derivative":{"exercise_price":17,"expiration_date":"2028-05-01","underlying":"Common Stock","underlying_shares":30508},"source":{"system":"sec-edgar","filing":"0001140361-18-021820","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000114036118021820/doc1.xml","form_type":"4"}},{"id":4317827,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-16T20:57:43.000Z","date":"2017-05-12","kind":"exercise","acquired":false,"shares":9987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015."}],"balance_after":85891,"derivative":{"exercise_price":6.6147,"expiration_date":"2025-08-25","underlying":"Common Stock","underlying_shares":9987},"source":{"system":"sec-edgar","filing":"0001140361-17-021016","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117021016/doc1.xml","form_type":"4"}},{"id":4317826,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-16T20:57:43.000Z","date":"2017-05-12","kind":"exercise","acquired":false,"shares":9980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019."}],"balance_after":204678,"derivative":{"exercise_price":4.4728,"expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":9980},"source":{"system":"sec-edgar","filing":"0001140361-17-021016","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117021016/doc1.xml","form_type":"4"}},{"id":4317825,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-16T20:57:43.000Z","date":"2017-05-12","kind":"exercise","acquired":true,"shares":9987,"price":6.6147,"value":66061.0089,"ownership":{"direct":true},"balance_after":32756,"source":{"system":"sec-edgar","filing":"0001140361-17-021016","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117021016/doc1.xml","form_type":"4"}},{"id":4317824,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-16T20:57:43.000Z","date":"2017-05-12","kind":"exercise","acquired":true,"shares":9980,"price":4.4728,"value":44638.544,"ownership":{"direct":true},"balance_after":22769,"source":{"system":"sec-edgar","filing":"0001140361-17-021016","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117021016/doc1.xml","form_type":"4"}},{"id":4354289,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-11T16:51:47.000Z","date":"2017-04-10","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019."}],"balance_after":214658,"derivative":{"exercise_price":4.4728,"expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001140361-17-015543","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117015543/doc1.xml","form_type":"4"}},{"id":4354288,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-11T16:51:47.000Z","date":"2017-04-10","kind":"exercise","acquired":true,"shares":3000,"price":4.4728,"value":13418.4,"ownership":{"direct":true},"balance_after":12789,"source":{"system":"sec-edgar","filing":"0001140361-17-015543","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117015543/doc1.xml","form_type":"4"}},{"id":4376214,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-21T22:05:56.000Z","date":"2017-03-20","kind":"exercise","acquired":false,"shares":21517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019."}],"balance_after":217658,"derivative":{"exercise_price":4.4728,"expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":21517},"source":{"system":"sec-edgar","filing":"0001140361-17-012870","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117012870/doc1.xml","form_type":"4"}},{"id":4376213,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-21T22:05:56.000Z","date":"2017-03-20","kind":"sale","acquired":false,"shares":11517,"price":20,"value":230340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan."}],"balance_after":9789,"source":{"system":"sec-edgar","filing":"0001140361-17-012870","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117012870/doc1.xml","form_type":"4"}},{"id":4376212,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-21T22:05:56.000Z","date":"2017-03-20","kind":"sale","acquired":false,"shares":10000,"price":19.6,"value":196000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan."}],"balance_after":21306,"source":{"system":"sec-edgar","filing":"0001140361-17-012870","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117012870/doc1.xml","form_type":"4"}},{"id":4376211,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-21T22:05:56.000Z","date":"2017-03-20","kind":"exercise","acquired":true,"shares":21517,"price":4.4728,"value":96241.2376,"ownership":{"direct":true},"balance_after":31306,"source":{"system":"sec-edgar","filing":"0001140361-17-012870","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117012870/doc1.xml","form_type":"4"}},{"id":4392232,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-03-10T00:22:15.000Z","date":"2017-03-09","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019."}],"balance_after":239175,"derivative":{"exercise_price":4.4728,"expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001140361-17-011297","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117011297/doc1.xml","form_type":"4"}},{"id":4392231,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-10T00:22:15.000Z","date":"2017-03-09","kind":"exercise","acquired":true,"shares":2500,"price":4.4728,"value":11182.0,"ownership":{"direct":true},"balance_after":9789,"source":{"system":"sec-edgar","filing":"0001140361-17-011297","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117011297/doc1.xml","form_type":"4"}},{"id":4478846,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T18:51:31.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":84000,"derivative":{"exercise_price":11.94,"expiration_date":"2027-01-24","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001140361-17-003155","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036117003155/doc1.xml","form_type":"4"}},{"id":4536769,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-02T00:01:17.000Z","date":"2016-11-30","kind":"grant","acquired":true,"shares":1289,"price":9.095,"value":11723.455,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"1,289 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":7289,"source":{"system":"sec-edgar","filing":"0001140361-16-088447","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036116088447/doc1.xml","form_type":"4"}},{"id":4589856,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-10-03T18:32:01.000Z","date":"2016-09-29","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019."}],"balance_after":241675,"derivative":{"exercise_price":4.4728,"expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001140361-16-081383","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036116081383/doc1.xml","form_type":"4"}},{"id":4589855,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":47978,"kind":"person","name":"Goeltz II Robert C.","position":1,"cik":"0001653881","reported_name":"Goeltz II Robert C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-10-03T18:32:01.000Z","date":"2016-09-29","kind":"exercise","acquired":true,"shares":4000,"price":4.4728,"value":17891.2,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001140361-16-081383","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036116081383/doc1.xml","form_type":"4"}}]}